
CLAIMS

1. Use of a CCR1 chemokine receptor antagonist and either a PD-1 inhibitor or a PD-L1 inhibitor in the preparation of medicament for use in combination for treating a subject having triple negative breast cancer, wherein a therapeutically effective amount of CCR1 chemokine receptor antagonist and a therapeutically effective amount of a PD-1 inhibitor or a PD-L1 inhibitor to be administered to the subject in need thereof,

wherein the CCR1 chemokine receptor antagonist has the formula (IIIb1a):




(IIIb1a)

wherein each A is N or CH and at least one A is N; R^1 is halogen; R^3 is selected from the group consisting of C_{1-8} alkyl, C_{3-8} cycloalkyl and C_{2-8} alkenyl; and R^8 is C_{1-8} alkyl; or a pharmaceutically acceptable salt thereof.


2. The use of claim **1**, wherein a CCR1 chemokine receptor antagonist and a PD-1 inhibitor are to be administered as a combination.

3. The use of claim **1**, wherein a CCR1 chemokine receptor antagonist and a PD-L1 inhibitor are to be administered as a combination.

4. The use of any one of claims **1** to **3**, wherein the CCR1 chemokine receptor antagonist is selected from the group consisting of:



and



,

or a pharmaceutically acceptable salt thereof.

5. The use of any one of claims **1**, **2** or **4**, wherein the PD-1 inhibitor is selected from the group consisting of pembrolizumab, nivolumab, IBI-308, mDX-400, BGB-108, MEDI-0680, SHR-1210, PF-06801591, PDR-001, GB-226, STI-1110.

6. The use of any one of claims **1**, **3** or **4**, wherein the PD-L1 inhibitor is selected from the group consisting of durvalumab, atezolizumab, avelumab, BMS-936559, ALN-PDL, TSR-042, KD-033, CA-170, CA-327, STI-1014, KY-1003, biosimilars thereof.

7. The use of any one of claims **1** to **6**, wherein the CCR1 chemokine receptor antagonist and the PD-1 inhibitor or the PD-L1 inhibitor are to be administered concomitantly.

8. The use of claim **7**, wherein the CCR1 chemokine receptor antagonist, and the PD-1 inhibitor or the PD-L1 inhibitor are to be administered in a combination formulation.

9. The use of any one of claims **1** to **6**, wherein the CCR1 chemokine receptor antagonist, and the PD-1 inhibitor or the PD-L1 inhibitor are to be administered sequentially.

10. The use of claim **9**, wherein the CCR1 chemokine receptor antagonist is to be administered prior to the PD-1 inhibitor or the PD-L1 inhibitor.


11. The use of claim **9**, wherein the CCR1 chemokine receptor antagonist is to be administered after the PD-1 inhibitor or the PD-L1 inhibitor.

12. The use of any one of claims **1** to **11**, wherein the CCR1 chemokine receptor antagonist is to be administered orally and the PD-1 inhibitor or the PD-L1 inhibitor is to be administered intravenously.

13. The use of any one of claims **1** to **12**, wherein the subject is a human subject.

14. A composition for use in treating a subject having triple negative breast cancer, comprising a therapeutically effective amount of a CCR1 chemokine receptor antagonist, a therapeutically effective amount of a PD-1 inhibitor or a PD-L1 inhibitor, and a pharmaceutically acceptable carrier or excipient,

wherein the CCR1 chemokine receptor antagonist has the formula (IIIb1a):




(IIIb1a)

wherein each A is N or CH and at least one A is N; R^1 is halogen; R^3 is selected from the group consisting of C_{1-8} alkyl, C_{3-8} cycloalkyl and C_{2-8} alkenyl; and R^8 is C_{1-8} alkyl; or a pharmaceutically acceptable salt thereof.


15. The composition of claim **14**, comprising the CCR1 chemokine receptor antagonist, the PD-1 inhibitor, and the pharmaceutically acceptable carrier or excipient.

16. The composition of claim **14**, comprising the CCR1 chemokine receptor antagonist, the PD-L1 inhibitor, and the pharmaceutically acceptable carrier or excipient.

17. The composition of any one of claims **14** to **16**, wherein the CCR1 chemokine receptor antagonist is selected from the group consisting of:



3.001



3.002

or a pharmaceutically acceptable salt thereof.

18. The composition of any one of claims **14**, **15** or **17**, wherein the PD-1 inhibitor is selected from the group consisting of pembrolizumab, nivolumab, IBI-308, mDX-400, BGB-108, MEDI-0680, SHR-1210, PF-06801591, PDR-001, GB-226, STI-1110.

19. The composition of any one of claims **14**, **16** or **17**, wherein the PD-L1 inhibitor is selected from the group consisting of durvalumab, atezolizumab, avelumab, BMS-936559, ALN-PDL, TSR-042, KD-033, CA-170, CA-327, STI-1014, KY-1003.